ClinicalTrials.gg
Not yet recruitingNCT07591597IGNITE-CRCUpdated May 18, 2026

A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

A Phase 1/2 interventional study of S-531011 and Fruquintinib in Metastatic Colorectal Neoplasms and Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer, sponsored by National Cancer Center Hospital East. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by National Cancer Center Hospital East · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies testing HMPL-013 in Colorectal Neoplasms — 33 open to participants now, 38 under way, 3 of them phase 3. HMPL-013 · Colorectal Neoplasms.

Planned enrollment
23rd of 61
68 · median 52
Started
2026
with 8 others
Phase 1/2
5 of 61
2 open now
Primary completion
2027-07
later than 23 of 37 live
Registered
57th of 61
by date

Among the 61 studies testing HMPL-013 in Colorectal Neoplasms, this one is the 23rd largest by planned enrollment, is one of 9 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 23 of the 37 other live ones, and was the 57th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

33 of the 61 studies testing HMPL-013 in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

28 more — sign in →

By country, each count listing its studies:

All 33 open studies →

About HMPL-013

HMPL-013: first FDA approval 2023 (FRUZAQLA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing HMPL-013 in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of the concurrent combination therapy of S 531011 + fruquintinib or S 531011 + fruquintinib + pembrolizumab in patients with MSS/pMMR colorectal cancer.

Read the detailed description

This study aims to evaluate the efficacy and safety of the concurrent combination therapy of S-531011 plus fruquintinib, or S-531011 plus fruquintinib plus pembrolizumab, in patients with MSS/pMMR colorectal cancer. Eligible participants include patients with metastatic colon or rectal cancer who are 18 years of age or older, have an ECOG Performance Status of 0-1, and have MSS or pMMR tumor status. After written explanation and the provision of written informed consent, participants will be enrolled.

The study consists of a Phase Ib part and a Phase II part. In the Phase Ib part (N = 6-12/Arm), participants will be assigned to Arm A or Arm B. Enrollment into Arm B will begin only after enrollment into Arm A has been completed in both phases.

Arm A consists of S-531011 (intravenous, once every 3 weeks) plus fruquintinib (5 mg orally once daily on Days 1-21 of a 28-day cycle).

Arm B consists of S-531011 (intravenous, once every 3 weeks), fruquintinib (5 mg orally once daily on Days 1-21 of a 28-day cycle), and pembrolizumab (200 mg, intravenous, once every 3 weeks).

In the Phase II part (N = 22/Arm), the recommended dose determined in the Phase Ib part will be used.

03

Conditions studied

  • Metastatic Colorectal Neoplasms
  • Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer

Keywords

  • Colorectal Neoplasms
  • Metastatic Colorectal Cancer
  • Microsatellite Stability
  • DNA Mismatch Repair
  • Receptors, CCR8
  • CCR8 Antagonists
  • Fruquintinib
  • Pembrolizumab
  • Antibodies, Monoclonal
  • Immune Checkpoint Inhibitors
  • VEGFR Inhibitors
  • Combination Drug Therapy
  • Phase Ib Clinical Trial
  • Phase II Clinical Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed unresectable adenocarcinoma of the colon or rectum.
  2. Confirmed microsatellite stable (MSS) or proficient mismatch repair (pMMR) status.
  3. Prior treatment with standard systemic chemotherapy and or intolerant* to such therapies. Standard chemotherapy must include all of the following:

    - Fluoropyrimidine, irinotecan, and oxaliplatin (with or without anti-VEGF antibody therapy)

    - For patients with RAS and BRAF wild-type tumors: prior treatment with anti-EGFR monoclonal antibody (cetuximab or panitumumab)

    - For patients with BRAF V600E mutation: prior treatment with a BRAF inhibitor (encorafenib)

    *For patients who relapse during chemotherapy or within 6 months after the last dose of postoperative adjuvant chemotherapy, that adjuvant therapy counts as prior systemic therapy.

  4. Presence of according to version 1.1.
  5. Age ≥ 18 years at the time of .
  6. (ECOG) performance status of 0 or 1.
  7. Laboratory values within 14 days prior to enrollment meeting all of the following (tests performed on the same weekday 2 weeks before the enrollment date are acceptable):

<!-- -->

  1. ≥ 1,500/mm³
  2. ≥ 9.0 g/dL
  3. count ≥ 75,000/mm³
  4. Total ≤ 1.5 × institutional (ULN)
  5. (GOT) ≤ 2.5 × ULN; ≤ 5 × ULN if liver are present
  6. ALT (GPT) ≤ 2.5 × ULN; ≤ 5 × ULN if liver metastases are present
  7. Creatinine ≤ 1.5 mg/dL
  8. Proteinuria ≤ 1+ or \< 1.0 g/24 h (urine protein-to-creatinine ratio \< 1 may be used; if 24-hour urine is collected, the measured value takes precedence) 8. No blood transfusion within 7 days prior to enrollment (a transfusion given on the same weekday 1 week earlier is considered ineligible).

9. Women of must have a negative pregnancy test within 14 days prior to enrollment. Both male and female participants must agree to use appropriate during the study and for 4 months after the last dose of study treatment. Female participants must also agree not to breastfeed during the study and for 4 months after the last dose. (Tests performed on the same weekday 2 weeks before the enrollment date are acceptable.) 10. Able to take oral medication. 11. Written informed consent obtained from the participant.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with fruquintinib for colorectal cancer.
  2. Prior treatment with any anti-CCR8 antibody, regardless of indication.
  3. Receipt of chemotherapy, radiotherapy, immunotherapy, or any antitumor therapy, or agents within 14 days prior to enrollment, or persistence of Grade ≥ 2 toxicities from prior therapies (excluding alopecia, hyperpigmentation, and peripheral sensory neuropathy).
  4. History of acute coronary syndrome (including myocardial infarction or unstable angina), coronary angioplasty, or stent placement within 6 months prior to enrollment.
  5. History or current findings of congestive heart failure of Class III or higher.
  6. Uncontrolled hypertension.
  7. Known central nervous system metastases. (If is clinically suspected, brain CT or MRI must be performed during screening.)
  8. Active double primary (simultaneous or metachronous with disease-free interval \< 2 years), except for carcinoma in situ or intramucosal carcinoma lesions considered curable by local therapy.
  9. Serious comorbidities requiring inpatient treatment (e.g., paralytic ileus, bowel obstruction, pulmonary fibrosis, uncontrolled diabetes, heart failure, myocardial infarction, angina, renal failure, hepatic failure, psychiatric disorders, cerebrovascular disorders, or transfusion-requiring ulcers).
  10. Active infections, including:

    - HBs antigen positive

    • Patients may be eligible if receiving nucleoside analog antiviral therapy and \< 20 IU/mL (1.3 log IU/mL).

      - HBs antibody positive or HBc antibody positive AND HBV-DNA positive

    • If HBV-DNA \< 20 IU/mL, the patient may be eligible. - antibody positive
    • Patients may be eligible if HCV-RNA is below the detection limit. - positive
    • Patients may be eligible if HIV infection is ruled out by confirmatory testing.

      • Other active infections requiring treatment.
  11. History of disease or chronic/recurrent autoimmune disease (patients with type 1 diabetes, hypothyroidism manageable with hormone replacement, or localized skin diseases such as vitiligo, psoriasis, or alopecia not requiring systemic therapy are eligible).
  12. Requirement for systemic or agents, or receipt of such therapy within 2 weeks prior to enrollment (treatment given on the same weekday 2 weeks earlier renders the patient ineligible), except for temporary administration for testing, allergic reactions, or edema associated with radiotherapy.
  13. Lack of willingness or inability to comply with study procedures.
  14. Considered unsuitable for the study by the principal investigator or sub-investigator.

Pregnancy and :

A woman of includes any female who has experienced menarche, has not undergone permanent sterilization (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), and is not . Postmenopause is defined as at least 12 consecutive months of amenorrhea without another medical cause. Women using oral contraceptives, intrauterine devices, or mechanical barrier methods are considered capable of becoming pregnant. If a female participant is determined to be not capable of becoming pregnant, this must be documented in source records.

Women must use effective contraception for at least 1 month prior to first study treatment, from the time of consent, and for at least 4 months after the last dose. Men must use effective contraception during study treatment and for at least 4 months after the last dose.

Acceptable contraception includes vasectomy or condom use for male participants or male partners, and tubal ligation, contraceptive pessary, intrauterine devices, or oral contraceptives for female participants or female partners.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Arm A S-531011 + Fruquintinib

    Participants receive S-531011 and fruquintinib. In the Phase Ib part, dose levels may vary according to the dose finding scheme. In Phase II, the recommended dose determined in Phase Ib will be used.

    Biological: S-531011 · Drug: Fruquintinib

  • Experimental
    Arm B S-531011 + Fruquintinib + Pembrolizumab

    Participants receive S-531011, fruquintinib, and pembrolizumab. In the Phase Ib part, dose levels of S-531011 and fruquintinib may vary according to the dose finding scheme. In Phase II, the recommended dose determined in Phase Ib will be used. Pembrolizumab is administered at a fixed dose throughout both the Phase Ib and Phase II parts.

    Biological: S-531011 · Drug: Fruquintinib · Biological: Pembrolizumab

Interventions

  • BiologicalAnti-CCR8 Monoclonal Antibody S-531011Studies of Anti-CCR8 Monoclonal Antibody S-531011Anti-CCR8 Monoclonal Antibody S-531011 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    S-531011 will be administered intravenously once every 3 weeks (q3w). In the Phase Ib part, A reduced dose of S-531011 may be used in Dose Level -1 according to the predefined dose-finding scheme by evaluating DLT profile. In the Phase II part, S-531011 will be administered at the recommended dose determined in the Phase Ib part.

  • DrugHMPL-013Studies of HMPL-013HMPL-013 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fruquintinib will be administered orally once daily on Days 1-21 of each 28-day cycle. In the Phase Ib part, fruquintinib will be started at 5 mg (Dose Level 0). A reduced dose of 4 mg may be used in Dose Level -1 according to the predefined dose-finding scheme by evaluating DLT profile. In the Phase II part, fruquintinib will be administered at the recommended dose determined in the Phase Ib part.

    Also known as: FRUZAQLA

  • BiologicalPembrolizumab

    Pembrolizumab will be administered intravenously at a dose of 200 mg once every 3 weeks (q3w).

    Also known as: KEYTRUDA

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT) Rate [Phase Ib Part]

    Percentage of participants experiencing dose-limiting toxicities (DLTs).

    Time frame: Up to 29 days after first dose

  2. Objective Response Rate (ORR) [Phase II Part]

    Objective response rate assessed by the principal investigator or sub-investigator.Participants treated at the recommended dose in Phase Ib are included.

    Time frame: From baseline to objective disease progression or death, assessed up to 24 months.

Secondary outcomes

  1. Maximum Observed Serum Concentration of S-531011 (Cmax)

    Maximum observed concentration of S-531011 in serum.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  2. Time to Maximum Observed Serum Concentration of S-531011 (Tmax)

    Time to reach the maximum observed serum concentration of S-531011.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  3. Area Under the Serum Concentration-Time Curve of S-531011 (AUC)

    Area under the serum concentration-time curve of S-531011.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  4. Terminal Elimination Half-Life of S-531011 (t1/2)

    Terminal elimination half-life of S-531011 estimated from serum concentration-time data.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  5. Anti-S-531011 Antibody (ADA) Titer

    Titer of anti-S-531011 antibodies measured to assess immunogenicity.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  6. Incidence of Anti-S-531011 Antibody (ADA) Positivity

    Proportion of participants with detectable anti-S-531011 antibodies.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  7. Neutralizing Anti-S-531011 Antibody (NAb) Titer

    Titer of neutralizing anti-S-531011 antibodies in participants who test positive for anti-S-531011 antibodies.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  8. Incidence of Neutralizing Anti-S-531011 Antibody (NAb) Positivity

    Proportion of participants with detectable neutralizing anti-S-531011 antibodies.

    Time frame: From the first through the ninth administration of S-531011 (each cycle is 21 days) and at 30 days after the final administration

  9. Duration of Response (DoR) [Phase Ib/II Part]

    Duration of confirmed objective response.

    Time frame: From first documented response until disease progression or death from any cause, whichever occurs first, assessed up to 12 months after the last subject is enrolled

  10. Disease Control Rate (DCR) [Phase Ib/II Part]

    Percentage of participants achieving CR, PR, or SD.

    Time frame: Up to 12 months after the last subject is enrolled

  11. Progression-Free Survival (PFS) [Phase Ib/II Part]

    Time from enrollment to radiological progression or death.

    Time frame: From enrollment until disease progression or death from any cause, whichever occurs first, assessed up to 12 months after the last subject is enrolled

  12. Overall Survival (OS) [Phase Ib/II Part]

    Time from enrollment to death.

    Time frame: From enrollment until death from any cause, assessed up to 12 months after the last subject is enrolled

  13. Incidence of Adverse Events [Phase Ib/II Part]

    Percentage of participants experiencing adverse events.

    Time frame: From first dose until 30 days after last dose for all adverse events, and thereafter for related adverse events up to 12 months after the last subject is enrolled

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jul 2027, 14 months later.

Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 14 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
May 18, 2026
StartEst.
May 2026
Primary completionEst.
Jul 2027
CompletionEst.
May 2029
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07591597
Lead sponsor
National Cancer Center Hospital East
Collaborators
Shionogi
Responsible party
Akihito Kawazoe (Chief, Department of Gastrointestinal Oncology, National Cancer Center Hospital East) — Principal investigator
First posted
May 18, 2026
Start date
May 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
May 2029 (estimated)
Last update
May 18, 2026

Study contacts

Akihito Kawazoe, MD
Contact
ignite-crc_core@east.ncc.go.jp
+81-4-7133-1111
Kazumasa Yamamoto, MD
Contact
ignite-crc_core@east.ncc.go.jp
+81-4-7133-1111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-CCR8 Monoclonal Antibody S-531011 · HMPL-013

Start the discussion